Understanding how metabolism drives acute myeloid leukemia
Interrogation of the oxidative-stress-induced leukemia program in vivo using metabolic imaging
This research explores how specific metabolic changes in leukemia cells could lead to new ways to treat acute myeloid leukemia (AML), especially for patients whose disease returns or resists current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11123417 on NIH RePORTER |
What this research studies
Acute myeloid leukemia (AML) is a complex cancer where many patients experience their disease returning or becoming resistant to initial treatments. This project aims to uncover unique metabolic features within AML cells that could be targeted with new medicines. We are particularly interested in how leukemia cells use sugar and other nutrients differently, focusing on an enzyme called PHGDH. By understanding and potentially blocking this enzyme, we hope to find new vulnerabilities in these cancer cells. This work builds on previous discoveries about leukemia's metabolism, seeking to develop more effective strategies for patients.
Who could benefit from this research
Good fit: This research is most relevant to patients with acute myeloid leukemia, especially those whose disease has returned or is no longer responding to current therapies.
Not a fit: Patients without acute myeloid leukemia or those whose disease does not involve the specific metabolic pathways being studied may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new drug targets and therapies for acute myeloid leukemia, particularly for patients who have relapsed or become resistant to existing treatments.
How similar studies have performed: Previous work by this research team has successfully identified new metabolic vulnerabilities in leukemia, providing a strong foundation for this current approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Keshari, Kayvan R — Sloan-Kettering Inst Can Research
- Study coordinator: Keshari, Kayvan R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.